



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/649,299
Filing Date	August 22, 2003
First Named Inventor	JW Corbett
Art Unit	1614
Examiner Name	not yet available
Attorney Docket Number	01320.US1

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

- | | | |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
<input type="checkbox"/> Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
A return-receipt postcard is enclosed.
Search report with references |
|--|--|--|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Pharmacia & Upjohn Company, John H. Engelmann (28,075)
Signature	<i>John Engelmann</i>
Date	MARCH 7, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Julie K. Lyons		
Signature	<i>Julie K Lyons</i>	Date	April 7, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				Atty. Docket No. 01320.US1		Serial No. 10/649,299	
				Applicant JW Corbett, et al.			
				Filing Date 8/27/03		1614	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	6,589,947 B1	July 8, 2003	Hamanaka et al.	514	183	
	AB	6,043,260	Mar. 28, 2000	Chen et al.	514	348	
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
	AC	EP 1097709A2	Oct. 26, 2000	Europe	A61K	31/426	
	AD	WO01/60806A2	Aug. 23, 2001	WIPO	C07D	241/00	
	AE	WO98/11075A1	Mar. 19, 1998	WIPO	C07D	241/20	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AF	M. Arato, et al., <i>Biol. Psychiatry</i> 25:355-359 (1989)					
	AG	C.M. Banki, et al., <i>Am. J. Psychiatry</i> 144:873-877 (1987)					
	AH	G. Battaglia et al., <i>Synapse</i> 1:572-581 (1987)					
	AI	C.W. Berridge and A.J. Dunn, <i>Brain Research Reviews</i> 15:71-100 (1990)					
	AJ	C.W. Berridge and A.J. Dunn, <i>Horm. Behav.</i> , 21:393-401 (1987)					
	AK	C.W. Berridge and A.J. Dunn, <i>Regul. Peptides</i> 16:83-93 (1986)					
	AL	J.E. Blalock, <i>Physiological Reviews</i> 69:1-32 (1989)					
	AM	N. Bodor, "Novel Approaches in Prodrug Design," <i>Drugs of the Future</i> , 6(3):165-182 (1981)					
	AN	D.R. Britton, et al., <i>Life Sci.</i> 31:363-367 (1982)					
	AO	K.T. Britton, et al., <i>Psychopharmacology</i> 86:170-174 (1985)					
	AP	K.T. Britton, et al., <i>Psychopharmacology</i> 94:306-311 (1988)					
	AQ	S.L. Buchwald, <i>J. Am. Chem. Soc.</i> , 124, 7421-7428 (2002)					
	AR	S.L. Buchwald, et al., <i>J. Am. Chem. Soc.</i> (2001), web addition, 123(43), 10770-10771					
	AS	S.L. Buchwald, <i>J. Org. Chem.</i> , 1158-1174 (2000)					
	AT	H. Bundgaard, "Design of Prodrugs: Bioreversible-Derivatives for Various Functional Groups and Chemical Entities," in <i>Design of Prodrugs</i> (H. Bundgaard, ed.), Elsevier, N.Y. (1985)					
	AU	E.B. De Souza, <i>Hosp. Practice</i> 23:59-71 (1988)					
	AV	E.B. De Souza, et al., <i>J. Neurosci.</i> 5:3189-3203 (1985)					
	AW	P.J. Fagan, et al., <i>J. Am. Chem. Soc.</i> 122, 5043-5051 (2000)					

<p>LIST OF REFERENCES CITED BY APPLICANT</p> <p>(Use several sheets if necessary)</p>		Atty. Docket No.	Serial No.
		01320.US1	10/649,299
		Applicant JW Corbett, et al.	
		Filing Date 8/27/03	1614
AX	R.D. France, et al., <i>Biol. Psychiatry</i> 23:86-88 (1988)		
AY	G. C. Fu, et al., <i>J. Am. Chem. Soc.</i> 122, 4020-4028 (2000)		
AZ	P.W. Gold, et al., <i>Am. J. Psychiatry</i> 141:619-627 (1984)		
BA	Grigoriadis, et al., <i>Neuropsychopharmacology</i> 2:53-60 (1989)		
BB	P.S. Herradura, et al., <i>Org. Lett.</i> , 2019-2022 (2000)		
BC	F. Holsboer, et al., <i>Psychoneuroendocrinology</i> 9:147-160 (1984)		
BD	G.F. Koob & K.T. Britton, In: <i>Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide</i> , E.B. De Souza & C.B. Nemeroff eds., CRC Press p 217-231 (1990)		
BE	G.F. Koob, <i>Persp. Behav. Med.</i> 2:39-52 (1985)		
BF	J. Krinkova, <i>Farmaco</i> , 57, 71-78 (2002)		
BG	<i>The Merck Manual of Diagnosis and Therapy</i> , 16 th Edition, 1582-1585 (1992)		
BH	J.E. Morley, <i>Life Sci.</i> 41:527-544 (1987)		
BI	A. R. Muci and S.L. Buchwald, <i>Topics in Current Chemistry</i> , vol. 219, 131-209 (2002)		
BJ	C.B. Nemeroff, et al., <i>Arch. Gen. Psychiatry</i> 45:577-579 (1988)		
BK	C.B. Nemeroff, et al., <i>Science</i> 226:1342-1344 (1984)		
BL	R. E. Notari, "Theory and Practice of Prodrug Kinetics," <i>Methods in Enzymology</i> , 112:309-323 (1985)		
BM	Akihiro Ohta, et al., <i>Chemical and Pharmaceutical Bulletin of Japan</i> , 27, 2027-2041 (1979)		
BN	J. Rivier, et al., <i>Proc. Natl. Acad. Sci. (USA)</i> 80:4851-4855 (1983)		
BO	R.M. Sapolsky, <i>Arch. Gen. Psychiatry</i> 46:1047-1051 (1989)		
BP	M. Shimazaki, "Reactions of Cyclohexyl and Aryl Pyrazinyl Sulfoxides" p898, Column 1, XP002266336 abstract and Heterocycles, Vol. 32, No. 5, (1991) p 937-947, Engl., Chemical Abstracts, Vol. 115, No. 11, (1991), Columbus, Ohio, US Abstract No. 114464c		
BQ	N.R. Swerdlow, et al., <i>Psychopharmacology</i> 88:147-152 (1986)		
BR	W. Vale, et al., <i>Science</i> 213: 1394-1397 (1981)		
BS	W. Vale, et al., <i>Rec. Prog. Horm. Res.</i> 39:245-270 (1983)		
Examiner		Date Considered	